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BRICHOS  –  a  novel  anti-amyloid  chaperone.  Studies  on  pro-
surfactant protein c. 
Abstract 
Lung surfactant protein C (SP-C) is a 35-residue, transmembrane (TM) peptide that 
is extremely hydrophobic and lacks known homologous proteins. Due to a high 
content in Val residues in the α-helical TM part, SP-C can spontaneously convert 
into β-sheet aggregates. We show here that SP-C forms amyloid in interstitial lung 
disease (ILD) caused by mutations in the C-terminal part of proSP-C (CTC).  
CTC has been predicted to contain a ∼100-residue BRICHOS domain, found in 
12 protein families with a wide range of functions and disease associations, such as 
respiratory  distress  syndrome,  dementia  and  cancer.  We  hypothesised  that  the 
BRICHOS domain can act as a chaperone, preventing proproteins from misfolding 
during biosynthesis. Recombinant CTC can bind to lipid associated non-helical SP-
C and this interaction results in an increased α-helical content in the mature SP-C 
peptide.  Wildtype  CTC  can  also  stabilize  proSP-C(1-58),  which  lacks  the 
BRICHOS  domain,  and  a  proSP-C  mutant  in  HEK293  cells.  CTC  binds 
selectively peptides derived from the TM part of SP-C and to residues that promote 
membrane insertion.  
CTC can also bind to other hydrophobic peptides, in particular the amyloid β-
peptide (Ab) associated  with Alzheimer disease. CTC  and Bri2  (associated  with 
familial  dementia)  BRICHOS  can  prevent  fibril  formation  of  Aβ40 and Aβ42 f a r  
below stoichiometric amounts, indicating that BRICHOS may be useful in future 
therapy.  
The crystal structure of the BRICHOS domain from CTC shows a novel fold 
with a central β-sheet flanked by α-helices. Many of the hydrophobic residues in 
the β-sheet are conserved and many of the point mutations associated with ILD 
coincide with these residues, suggesting that they are involved in the function of the 
BRICHOS domain, possibly by binding substrate peptides. 
Taken  together,  results  in  this  thesis, suggest that BRICHOS is a novel anti-
amyloid  chaperone  domain  and  mutations  that  lead  to  BRICHOS  dysfunction 
cause ILD and amyloid disease. 
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Abbreviations 
Three and one letter codes for the 20 naturally occurring amino acids 
 
Alanine                 Ala               A 
Arginine                Arg                R 
Asparagine              Asn                N 
Aspartic acid            Asp                D 
Cysteine                Cys                C 
Glutamic acid           Glu                E 
Glutamine              Gln                Q 
Glycine                 Gly               G 
Histidine                His               H 
Isoleucine               Ile                I 
Leucine                 Leu                L 
Lysine                   Lys               K 
Methionine             Met              M 
Phenylalanine           Phe                F 
Proline                  Pro               P 
Serine                   Ser               S 
Threonine              Thr                T 
Tryptophan             Trp                W 
Tyrosine                Tyr                Y 
Valine                   Val               V 
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Other abbreviations used 
 
Aβ            Amyloid β-peptide 
AD           Alzheimer’s disease 
APP            Amyloid-β precursor protein 
AUC         Analytical ultra centrifugation 
Bis-ANS      1,1’-bis(4-anilino-5,5’-naphtahalenesulfonate) 
CD           Circular dichroism 
CTC          C-terminal part of proSP-C 
DPPC          Dipalmitoyl-phosphatidylcholine 
DSC          Differential scanning calorimetry 
ER            Endoplasmic reticulum 
ESI-MS       Electrospray ionisation mass spectrometry 
FBD          Familial British dementia 
FDD          Familial Danish dementia 
GKN1        Gastrokine 1  
GKN2        Gastrokine 2 
HEK cells     Human embryonic kidney cells 
HSP            Heat shock proteins 
HDX         Hydrogen deuterium exchange 
ITM2A       Integral transmembrane protein 2A 
ITM2B       Integral transmembrane protein 2B 
ITM2C       Integral transmembrane protein 2C 
kDa           kilo Dalton 
LB            Lamellar body 
LECT1  Leukocyte cell-derived chemotaxin 1(Chondromodulin) 
MALDI       Matrix assisted laser desorption ionization 
MVB         Multivesicular body 
MS            Mass spectrometry 
POPC        Palmitoyl-oleoyl-phosphatidylcholine 
proSP-C      Surfactant protein C precursor 
SDS           Sodium dodecyl sulfate 
SEC            Size exclusion chromatography 
SP-A          Surfactant protein A 
SP-B          Surfactant protein B 
SP-C         Surfactant protein C 
ThT          Thioflavin T 
TM           Transmembrane 
TNMD       Tenomodulin   11 
1  Introduction 
1.1  BRICHOS domain 
The BRICHOS domain was recently discovered by Sanchez-Pulido et al, in 
four different protein families; Bri2, Chondromodulin-1, CA11 and SP-C 
(Sanchez-Pulido et al., 2002). The definition of a BRICHOS domain is 
solely based on sequence alignments and since 2002 the number of known 
proteins with a BRICHOS domain has grown and it has been found in over 
300  proteins in 12 distantly related  protein families. The  proteins  have a 
very wide range of functions and disease associations, spanning from cancer 
to  interstitial  lung  disease.  The  twelve  different  family  members  in  the 
BRICHOS  family  are  (in  the  order  of  sequence  similarities  to  the 
BRICHOS domain of prosurfactant protein C(proSP-C)): proSP-C, group 
C,  gastrokines  1  and  2  (GKN1,  GKN2),  group  B,  chondromodulin 
(LECT1), tenomodulin (TNMD), a small group of two proteins, group A, 
integral  transmembrane  protein  2A,  C  and  B  (ITM2A,  ITM2C  and 
ITM2B) (Hedlund et al., 2009). 
 
BRICHOS  proteins  have  four  different  regions;  hydrophobic,  linker, 
BRICHOS  and  C-terminal (fig.  1). The  only exception is the proSP-C 
family, where the BRICHOS domain is the last region. The hydrophobic 
region shows a high conservation in all families and is thought to be either a 
transmembrane (TM) region or a signal peptide or it can function as both as 
in the case of proSP-C (Keller et al., 1991, Conkright et al., 2001). The 
linker region only shows a high conservation in proSP-C, indicating that 
this region is of specific importance here. Although the conservation is high 
within each family, e.g. the proSP-C family, there are only three residues 
that are strictly conserved in all 12 BRICHOS families; one Asp and two   12 
Cys residues and all three are located in the BRICHOS region. The areas 
around  these  strictly  conserved  residues  also  show  a  high  degree  of 
conservation. The two conserved cysteines form a disulfide bridge in proSP-
C (paper IV) and are suggested to form a disulfide bridge in GKN2 (Westley 
et al., 2005) and this is likely also true for the other families. The C-terminal 
region is highly conserved in the C-group and is well conserved in ITM2, 
TNMD and in LECT1.  Although the sequence identity  between the 12 
protein families is low, e.g. below 25% sequence identity between human 
Bri2  and  proSP-C,  the  secondary  structure  predictions  of all 12 families 
show  similar  structures.  Up  until  now  the  structure  and  function  of  the 
BRICHOS domain has been unknown (Hedlund et al., 2009). 
 
Figure 1. The four different regions in the BRICHOS proteins; Hydrophobic in green, 
linker in grey, BRICHOS region in blue and the C-terminal in yellow color. 
1.1.1  Pro-surfactant protein C 
Surfactant protein C (SP-C) is together with surfactant protein B (SP-B) and 
phospholipids responsible for lowering the surface tension at the alveolar air-
water interface and by doing so preventing the lungs from collapse at end 
expiration  (Whitsett  and  Weaver,  2002).  Human  SP-C  is  encoded  by  a 
single gene (SFTPC) located on chromosome 8, that contains 6 exons, but 
only 5 of them are translated (Fisher et al., 1988, Glasser et al., 1988). SP-C 
is produced in the alveolar type II epithelial cells from a 21 kDa precursor 
(Beers et al., 1994), proSP-C, which contains four different regions; a short 
N-terminal  segment  that  is  located  in  the  cytosol  and  is  important  for 
intracellular trafficking, a 35 amino acid long TM region that makes up the 
main  part  of  mature  SP-C,  a  linker  region  followed  by  a  BRICHOS 
domain that is located in the endoplasmic reticulum (ER) lumen (fig. 2) (Li 
et al., 2004, Conkright et al., 2001, Keller et al., 1991).    13 
 
Figure 2. Schematic structure of proSP-C. The position of the first residue of each region 
is indicated.  The N-terminal is shown in light green and the transmembrane (TM) and 
mature SP-C in darker green. The CTC (the C-terminal of proSP-C) is presented in grey for 
the  linker  and  in  blue  for  the  BRICHOS  domain.  The  strictly  conserved  residues  in  all 
BRICHOS families are marked with red color. 
The mature SP-C peptide mainly consists of an α-helix. This helix is 
discordant,  i.e. i t  i s  c o m p o s e d  o f  a m i n o  a c i d s  w i t h  a  h i g h  β-strand 
propensity, primarily Ile and Val (Kallberg et al., 2001). Once the helix has 
formed in the membrane it is stable, but taken out from its phospholipid 
environment it can unfold and convert into β-sheet aggregates and amyloid-
like fibrils (Szyperski et al., 1998, Gustafsson et al., 1999). Synthetic SP-C 
analogues  with  the  poly-Val  stretch,  cannot  fold  into  an  α-helix 
conformation,  but  instead  forms  insoluble  aggregates  (Johansson  et  al., 
1995).  Therefore  leucine  (with  high  helix  propensity  (Johansson  et  al., 
2010)) was introduced instead, and synthetic SP-C analogues with poly-Leu 
can fold into a stable helical conformation and these analogues show almost 
the same surface activity as native SP-C (Palmblad et al., 1999, Nilsson et 
al., 1998).  
Biosynthesis of proSP-C 
ProSP-C is synthesized in the alveolar type II cells as an integral membrane 
protein with a type II orientation in the ER membrane with its C-terminal 
in the ER lumen and the N-terminal in the cytosol (Keller et al., 1991, 
Beers  et  al.,  1994).  Expression  of  mature  SP-C  without  its  N- a n d  C -
terminal  parts  results  in  aggregation  of  mature  protein  in  the  secretory 
pathway, indicating that the proparts are necessary for maturation (Beers et 
al., 1998, Conkright et al., 2001).  
 
ProSP-C  gets  posttranslationally  modified  with  palmitate  and 
proteolytically cleaved (fig. 3). The first to happen is palmitoylation of two 
Cys residues (5 and 6 in the mature peptide, fig. 5). This probably takes   14 
place in the cis-Golgi network (Vorbroker et al., 1992). To generate mature 
SP-C, proteolytic events take place in four steps. The C-terminal domain is 
removed in two steps, first a 16 kDa intermediate is generated and after that 
a 7 kDa intermediate. Both cleavages take place in the multi vesicular bodies 
(MVBs) (Solarin et al., 2001, Beers et al., 1994) as does the third step that 
removes the first 9 N-terminal residues. The fourth and last step occurs in 
the  lamellar  bodies  (LBs)  where  12  amino  acids  of  the  N-terminal  get 
proteolytically  cleaved  off  (Vorbroker  et  al.,  1995,  Beers  et  al.,  1994, 
Johnson et al., 2001, Solarin et al., 2001). Cathepsin H, a cysteine proteinase 
(Brasch et al., 2002) has been implicated in the processing of proSP-C. This 
enzyme  alone  can  however  not  process  the  proprotein  into  the  mature 
peptide, which means that there are still unidentified proteases that must be 
involved in the process. SP-B and SP-C are stored in the LBs where the 
protein is assembled in densely packed bilayers (Haagsman and van Golde, 
1991). The LBs fuse with the plasma membrane and release their contents 
into the liquid layer that covers the epithelial surface. After this event, the 
lipid vesicles with proteins gets rearranged into tubular myelin, which is a 
highly ordered array of phospholipids and proteins, and then inserted into 
the monolayer (Vorbroker et al., 1995). 
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Figure 3. Biosynthesis in alveolar type II cells. Human proSP-C is synthesized as a 191-
197 amino acid integral TM protein. The precursor protein gets palmitoylated in the Golgi 
network and proteolytically cleaved in several steps in the MVBs and LBs. 
Mutations in the proSP-C gene 
Mutations in the SFTPC gene are associated with interstitial lung disease 
(ILD) with intracellular protein aggregates (Nogee et al., 2001, Nogee et al., 
2002). There are about 50 known mutations and the majority of them are 
located  in  the  C-terminal  part  of  the  precursor  protein  (linker  and 
BRICHOS domain) (paper IV). The mutations have been found in patients 
spanning from newborn to adult and about half of them arise spontaneously 
and the rest are inherited. The age of onset and the phenotype can differ a 
lot between individuals that carry the same mutation (Hamvas, 2006).  
 
  Some of the SFTPC gene mutations have been more thoroughly studied. 
The most common is the I73T mutation, located in the linker region of 
proSP-C. Staining lung tissue from patients with proSP-C(I73T) mutation 
with antibodies against proSP-C reveal a diffuse pattern of the alveolar type 
II  cells,  which  indicates  that  this  mutation  is  associated  with  abnormal 
trafficking and intracellular accumulation of protein. Immunohistochemical   16 
analyses  also  showed  SP-B,  proSP-B,  aberrantly  processed  proSP-C  and 
high levels of SP-A in the lung of affected patients, and the surfactant lipid 
composition in the alveolar type II cells was also altered.  Mutant proSP-C 
ended up in early endosomes in transfected A549 epithelial cells (Tredano et 
al., 2004, Brasch et al., 2004, Woischnik et al., 2010). The E66K mutation 
is  also  located  in  the  linker  region  and  lung  histology  studies  showed 
abnormal processing of proSP-C and an increased amount of SP-A. When 
transfected  into  A549  cells,  proSP-C(E66K)  ended  up  in  the  early 
endosomes (Stevens et al., 2005). 
 
Deletion of exon 4 (Δexon4) due to a mutation that affects the splicing of 
the SFTPC gene, results in reduced amounts of proSP-C and a total lack of 
mature  SP-C  in  the  bronchoalveolar  lavage  fluid  (BAL)  (Nogee  et  al., 
2001). This is the first proSP-C mutation described. In different cell lines 
the mutation causes misfolding of the proSP-C, ER stress and induction of 
the  unfolded  protein  response,  leading  to  disrupted  lung  morphology 
(Mulugeta  et  al.,  2007,  Bridges  et  al.,  2003).  The  Δexon4  mutation  is 
located in the BRICHOS region of proSP-C, like the L188Q mutation. 
This mutation is located next to one of the strictly conserved Cys residues. 
The age of onset differs a lot between patients in one described kindred, and 
electron  microscopy  of affected lungs revealed alveolar type II cells with 
abnormal  lamellar  bodies  (Thomas  et  al.,  2002).  Cells  transfected  with 
proSP-C(L188Q) show misfolded proSP-C and upregulation of ER stress 
markers (Maguire et al., 2010, Lawson et al., 2008). 
 
ProSP-C  knock-out  mice  (strain  Swiss  black  mice)  showed  mild 
abnormalities of lung function with decreased stability of surfactant film at 
low lung volumes (Glasser et al., 2001). Mice of the same strain were treated 
with  bleomycin  to  induce  lung  fibrosis  and  the  SP-C  knock-out  mice 
showed a greater weight loss, higher mortality and a much slower recovery 
than the wildtype mice (Lawson et al., 2005). In another mouse strain (Sv 
strain)  the  proSP-C  knock-out  mice  get  progressive  inflammatory  lung 
disease (Glasser et al., 2003). ProSP-C deficiency is thus not lethal and SP-C 
does not appear to be critical for surfactant function, at least not acutely in 
mice.  The  differences  observed  between  mice  strains  suggest  that  the 
phenotype  associated  with  deficiency  of  proSP-C  may  be  influenced  by 
environmental or genetic factors. 
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All proSP-C mutations found so far have been on one allele only. Why 
this leads to lung disease is not clear but  possible mechanisms have been 
suggested. The low levels or total lack of mature SP-C could be the result of 
a  toxic  gain  of  function  or  a  dominant  negative  effect  i.e t h e  m u t a t e d  
protein  aggregates  with  the  wt  protein  and  this  will  lead  to  lung  disease 
(Wang et al., 2003). Alternatively, the production of misfolded proSP-C is 
difficult to handle for the protein degradation system and this will lead to 
ER stress, and later on, apoptosis and ILD (Maguire et al., 2010). 
1.1.2  Group C 
The  suggested  name  for  this  protein  is:  BRICHOS  domain-containing 
protein C16orf79 (www.uniprot.org) and the proteins in this group can be 
found in humans down to Drosophila melanogaster. In humans the protein is 
suggested to be 260 amino acids long and to have a N-glycosylating site. 
The C-terminal region in this group is highly conserved (Hedlund et al., 
2009). 
1.1.3  GKN2, GKN1 and group B. 
GKN2, GKN1 and group B are closely related and in GKN1 and GKN2 
the hydrophobic region may constitute a signal sequence instead of a TM 
segment (Hedlund et al., 2009).  
GKN2 
In humans, GKN2 or TFIZ1/GDDR, is a 184 amino acid long pro-protein 
expressed in gastric mucosa. It contains three Cys residues, two of them are 
involved in intramolecular binding and one Cys has been shown to form a 
disulfide  bridge  with  the  trefoil  factor  family  1(TFF1)  protein.  The 
TFF1:TFIZ1 heterodimer has been found in gastric mucosa where it could 
act  as  a  tumor  suppressor  (Westley  et  al.,  2005).  Others  have  found  the 
protein in mouse and named it blottin. Blottin binds to mouse TFF2 and is 
found in the gastric epithelial surface and foveolar epithelial cells where it 
may be involved in gastrointestinal mucosal maintenance (Otto et al., 2006). 
GKN1 
GKN1 is a 18 kDa pro-protein  that  is  synthesized  in  cells  of  the  gastric 
antrum mucosa (Martin et al., 2003). The function of GKN1 is not known 
but it has a suggested role in mucosal protection and it has also been proven 
to be down regulated in gastric carcinoma (Oien et al., 2004).    18 
Group B 
This group likely represents a novel gastrokine, GKN3 that is synthesized as 
a  19  kDa  proprotein  in m i c e .  T h e  g e n e  h a s  b e c o m e  n o n f u n c t i o n a l  i n  
humans due to a recent mutation. It has been proposed to be associated with 
gastric atrophy and to take part in the host response to Helicobacter pylori in 
mouse (Menheniott et al., 2010). 
 
1.1.4  LECT1  
LECT, Leukocyte cell-derived chemotaxin 1 or chondromodulin, 1 is an 
abundant protein in fetal bovine cartilage. The protein is synthesized as a 
335  amino  acid  proprotein  that  gets  post-translationally  modified  by 
glycosylation  and  proteolytically  cleaved  by  furin  to  yield  a  28  kDa 
glycoprotein  (Azizan  et  al.,  2001).  LECT1  is  associated  with 
chondrosarcoma and the expression is reduced in benign cartilage tumors 
(Hayami et al., 1999) and it also inhibits angiogenesis in cartilage (Hiraki et 
al., 1997). 
 
1.1.5  TNMD 
The 317 residue proprotein is assumed to be a type II membrane protein. It 
has  two  glycolsylation  sites  and  it  contains  eight  Cys  residues  in  the  C-
terminal region. The C-terminal resembles the C-terminal in LECT1 that 
has  been suggested to  have an antiangiogenic activity (Shukunami et al., 
2001). 
1.1.6  Small group of two proteins and group A 
None of the proteins in these two groups have been investigated. 
1.1.7  ITM2A, ITM2B and ITM2C (Bri proteins) 
The Bri proteins can be divided into Bri1 (ITM2A), Bri2 (ITM2B) and Bri3 
(ITM2C). 
The Bri1 protein  
The  Bri1  protein  is  a  263  amino  acids  long  protein  that  has  a  possible 
glycosylation site, like the rest of the proteins in the family. Bri1 has been 
reported to be involved in chondrogenic differentiation (Deleersnijder et al., 
1996, Van den Plas and Merregaert, 2004) Bri1 expression is induced in T 
cells  upon  activation  and  it  localizes  to  the  Golgi  apparatus,  large 
cytoplasmic vesicles and to the cell surface (Kirchner and Bevan, 1999).   19 
The Bri2 protein 
The Bri2 proprotein is a 266 amino acid residue long type II transmembrane 
protein  (fig.  4).  The  protein  gets  post-translationally  modified  by  N-
glycosylation and proteolytic cleavage at three positions. Furin cleaves in the 
C-terminal region and this cleavage generates ABri23, a 23 residue peptide 
(Kim et al., 2002, Kim et al., 1999). The BRICHOS domain is released 
from  the  membrane  bound  N-terminal  by  ADAM10  and  cleavage  by 
SPPL2a/2b releases the intracellular domain (Martin et al., 2008). 
 
Figure 4. Schematic structure of Bri2. The position of the first residue of each region is 
indicated. The N-terminal is shown in light green and the TM in darker green. The linker 
region is represented in grey, the BRICHOS domain in blue and the C-terminal region in 
yellow color. The strictly conserved residues in all BRICHOS families are marked with red 
color.  
 
The Bri2 protein is associated with familial British and Danish dementia 
(FBD and FDD). Both diseases have an early onset, median ages of onset, 48 
years in FBD and 27 years in FDD. The diseases are similar to Alzheimer’s 
disease  (AD)  and  are  characterized  by  extracellular  amyloid  plaques  with 
neurodegeneration (Rostagno et al., 2005). A single point mutation gives an 
Arg codon instead of a stop codon in FBD and this results in a 277 amino 
acid residue long precursor protein (Vidal et al., 1999). In FDD, an insertion 
of 10 nucleotides just before the stop codon also results in a 277 amino acid 
long precursor protein (Vidal et al., 2000). After furin cleavage, a 34 amino 
acid long amyloidogenic peptide is released in both FBD and FDD (Kim et 
al., 2002, Kim et al., 1999). The amyloidogenic peptides (ABri in FBD and 
ADan in FDD) show a 100% sequence identity in their first 22 residues but 
are  completely  different  in  their  last  12  residues.  Both  ABri  and  ADan 
isolated from amyloid plaques have been posttranslationally modified at the 
N-terminus,  both  peptides  have  pyroglutamate  instead  of  glutamic  acid 
(Tomidokoro et al., 2005). This modification has been observed in other 
peptides in brain amyloids e.g the Aβ peptide. This modification changes the 
charge and increases the β-sheet content, which makes both ABri and ADan   20 
more prone to form aggregates and polymerize. Soluble forms of both ABri 
and ADan have been found in the body fluids of patients and ABri has also 
been found in systemic amyloid deposits in peripheral tissue (Ghiso et al., 
2001). 
 
Lately, ideas to use the Bri2 protein as a possible molecular target for an 
anti-amyloid therapy for AD have been put forward. Immunohistochemical 
studies  of  amyloid  deposits  in  FDD  revealed  the  presence  of  Aβ,  which 
suggests  that  these  two  molecules  can  interact  during  misfolding  and 
aggregation, (Tomidokoro et al., 2005, Rostagno et al., 2005). The Bri2 
protein has also been shown to interact with the amyloid precursor protein 
(APP)  in  cell  cultures  and  the  interaction  affected  the  APP  processing 
(Fotinopoulou  et  al.,  2005). T h e  s o l u b l e  A B r i 2 3  p e p t i d e  h a s  a l s o  b e e n  
shown  to  bind  to  monomers  and  prevent  Aβ f r o m  f o r m i n g  o l i g o m e r i c  
aggregates, both in vitro and in vivo (Kim et al., 2008, Matsuda et al., 2009b). 
Finally, a recombinant human BRICHOS domain of Bri2 can bind to Aβ1-
40 and to the soluble ABri23 peptide in vitro (Peng et al., 2010). 
The Bri3 protein 
The Bri3 is a 267 amino acid long protein of unknown function. It is mostly 
expressed in the  brain as a  type  II  TM  protein  with an extracellular  C-
terminal and it gets posttranslationally modified by N-glycosylation (Vidal et 
al., 2001) and proteolytically cleaved by furin (Wickham et al., 2005). So 
far, no diseases have been associated with the Bri3 protein. The amino acid 
sequence of Bri3 is 44% identical with the sequence of Bri2 and since Bri2 
has been proven to interact with APP and the Aβ peptide the Bri3 was also 
studied in a similar way. Bri3 interacts with APP in cell culture and reduces 
both  α- and  β-APP  cleavage  by  blocking the access for  these secretases 
(Matsuda et al., 2009a). 
1.2  Protein folding and chaperones 
1.2.1  Protein folding 
Proteins  are  made  up  of  20  different  naturally  occurring  amino  acid 
residues. The specific sequence of amino acids is unique for each protein. 
The residues are connected via peptide bonds and the primary structure of a 
protein is defined by the order of the residues. The secondary structure, α-
helices or β-sheets, is held together by hydrogen bonds between atoms in 
the backbone of the polypeptide chain. The secondary structure elements   21 
assemble  into  a  three  dimensional  tertiary  structure,  stabilized  by  strong 
electrostatic and hydrophobic interactions and sometimes by disulfide bonds. 
The quaternary structure is an assembly of several polypeptide chains.  
 
Protein  folding  follows  thermodynamic  principles.  Many  attempts  have 
been  made  to  establish  general  folding  principles  but  so  far  no  one  has 
succeeded. It has been shown that the driving force for the folding process is 
the  search  for  the  lowest  energy  state  and  in  most  cases  folded  proteins 
represent  the  most  thermodynamically  stable  conformation,  i.e. t h e  
conformation with the lowest potential energy (Dobson, 2003). During this 
process the protein forms several different intermediate steps before it finally 
reaches its native conformation. All different conformations that the protein 
can adopt during the folding process are associated with free energy. If the 
free  energy  is  plotted  against  the  corresponding  conformation  an  energy 
landscape can be created which visualizes the proteins way from an unfolded 
to a folded state (Plotkin and Onuchic, 2002, Dobson, 2001). 
 
Protein folding in the cell is an even more complicated procedure due to 
the very crowded environment. The concentration of macromolecules in 
the cell can be as high as 400 mg/ml and this limits the available volume 
inside the cell for the growing polypeptide chain (Ellis and Minton, 2003). 
When the polypeptide chain is synthesized, it exposes hydrophobic regions, 
which can interact with other hydrophobic cellular constituents and this can 
lead  to  a  failure  for  the  protein  to  fold  into  its  functionally  native  state 
(Radford, 2000). Misfolding of the protein can result in malfunction and the 
formation of protein aggregates. Human misfolding diseases originate when 
the  proteins  adopt  non-native  structures,  which  will  lead  to  aggregation 
with intra and/or extracellular deposits. Nature has tried to overcome these 
challenges  by  a  number  of  systems  to  support  folding  and  one  of  these 
systems are the molecular chaperones (Ellis, 1990). 
1.2.2  Molecular Chaperones  
All cells need chaperones to assist in the folding of the newly synthesized 
polypeptide chain, so it does not get involved in inappropriate interactions 
(Hartl, 1996). Molecular chaperones are currently defined “as a large and 
diverse  group  of  proteins  that  share  the  property  of  assisting  the  non-
covalent folding and unfolding and the assembly and disassembly of other 
macromolecular  structures,  but  are  not  permanent  components  of  these 
structures  when  they  are  performing  their  normal  biological  functions” 
(Ellis, 2006).    22 
 
Proteins  can  also  misfold  or  unfold  because  of  cellular  stress  e.g. 
temperature changes, genetic mutations or ageing. When the cell is under 
stress the translation of heat shock proteins (HSP) is induced. There are a 
number  of  heat  shock  proteins  and  almost  all  of  them  function  as 
chaperones. The heat shock proteins can be classified into six main families: 
HSP100,  HSP90,  HSP70,  HSP60,  HSP40  and  the  small  HSPs.  The 
classification is based on molecular mass (Muchowski and Wacker, 2005). 
The HSP70s consist of a C-terminal substrate binding domain (SBD) and an 
N-terminal  ATP-binding  domain.  The  non-native  proteins  have exposed 
hydrophobic areas that can bind to the SBD of the HSPs. The binding and 
release is then repeated in cycles until the protein has folded into its native 
structure  (Beckerman,  2009).  HSP70  together  with  its  co-chaperone, 
HSP40,  has  been  shown  to  participate  in  assembly  of  proteins  into 
macromolecular complexes, aggregation prevention and protein degradation 
(Broadley and Hartl, 2009). HSP90 together with HSP70 and HSP40, have 
an early effect in the amyloid β-peptide 1-42 (Aβ1-42) fibril formation (Evans 
et al., 2006).  
 
There are also extracellular chaperones, like apolipoprotein J, also called 
clusterin. Clusterin has been found to inhibit amorphous aggregation of a 
number of proteins and to inhibit Aβ and α-synuclein from fibril formation 
(Humphreys  et  al.,  1999,  Yerbury  et  al.,  2007).  Haptoglobulin  and  α2-
macroglobulin are two glycoproteins that also have been suggested to work 
as  extracellular  chaperones.  Both  proteins  can  bind  to  Aβ1-42,  calcitonin 
(associated  with  localized  amyloidosis),  and  lysozyme  (associated  with 
familial  systemic  amyloidosis)  and  inhibit  the  formation  of f i b r i l s  in  vitro 
(Yerbury et al., 2009). α2-macroglobulin can also suppress the formation of 
amorphous aggregates of different proteins under stress (French et al., 2008).  
 
Some  chaperones  function  by  minimizing  the  risk  for  partially  folded 
proteins  to  aggregate  with  each  other  by  offering  a  platform  for  the 
polypeptide to be able to fold without the disturbance from other proteins 
or cellular elements. These chaperones have little or no sequence specificity 
for the polypeptide chains that they bind to and are often ATP dependent 
(Beckerman, 2009). Steric chaperones on the other hand, bind specifically 
and ad structural (steric) information to the polypeptide chain that is in the 
process of folding and in this way the chaperones can control the folding. 
These chaperones are ATP independent.  Some of the steric chaperones are 
localized in the N-terminal part as a prosequence and act as intramolecular   23 
chaperones that  bind to  the rest  of the  chain (Inouye, 1991).  When  the 
protein has folded correctly the N-terminal chaperone gets cleaved off and 
degraded. The prosequence chaperones can also be added in vitro to partially 
folded chains in trans and still assist in the folding of the polypeptide chain 
that have failed to fold and instead adopted a compact, partially folded state 
that resembles that of a molten globule (Ellis, 1998).  
 
1.3  Misfolding and amyloid 
Misfolding of proteins is the cause of almost thirty amyloid diseases in man 
e.g. AD, Creutzfeldt-Jakob disease, Parkinson’s disease and type II diabetes 
(Sipe et al., 2010). Even though the proteins responsible for the diseases do 
not have any sequence identity they all form amyloid fibrils which have the 
same morphology. These fibers are insoluble, protease resistant and have β-
sheet  structure.  All  amyloid  fibers  consist  of  β-strands  that  runs 
perpendicular to the axis of the fiber (cross β-structure) (Eanes and Glenner, 
1968). The fibers give distinct X-ray signals at 4.7 Å and at 10-11 Å, are 
unbranched and around 10 nm in diameter (Makin and Serpell, 2005). To 
be  designated  amyloid  it  must  occur  in  tissue  deposits,  and  staining  with 
Congo red should give green birefringence under cross-polarized light (Sipe 
et al., 2010). There are two different types of the amyloid diseases, localized 
or systemic. In the localized amyloidosis, only one organ is affected e.g. the 
brain in Alzheimer’s disease, while in the systemic amyloidosis, deposits are 
found in a wide range of tissues and organs e.g. lysozyme amyloidosis.  
 
The formation of amyloid fibrils can occur when the native protein is 
destabilized and has started to form aggregates. Amyloid fibril formation, a 
nucleation  dependent  process  (Jarrett  and  Lansbury,  1993),  typically  has 
three phases: the lag phase, elongation phase and the equilibrium. The lag 
phase e n c o m p a s s e s  the  formation  of  soluble  oligomers  or  nuclei  from 
monomers, which is a rather slow process, and these oligomers are required 
to seed the fibril growth. This step can be accelerated by the addition of 
seeds  (preformed  nuclei).  The  next  step,  the  elongation  phase,  is  on  the 
other hand rather fast where the oligomers start to form fibrils. In the last 
steady state phase, the monomers and fibrils are at an equilibrium. 
1.3.1  Amyloid β-peptide (Aβ) 
 AD is a neurodegenerative disorder characterized by cerebral extracellular 
Aβ d e p o s i t s  a n d  i n t r a c e l l u l a r  t a n gles  made  of  the  protein  tau.  Alois   24 
Alzheimer, a German physician, first described AD in 1907 and the disease 
is the commonest cause of dementia in elderly (Fratiglioni et al., 2000). The 
extracellular deposits or senile plaques in the brain of an AD patient, contain 
amyloid  fibrils  formed  by  the  Aβ-peptide  (Glenner  et  al.,  1984).  Aβ i s  
derived  from  the  amyloid-β p r e c u r s o r  p r o t e i n  ( A P P ) ,  w h i c h  i s  a  t y p e  I  
transmembrane  protein  with  the  N-terminal  located  in  the  extracellular 
space.  APP  is  processed  in  several  steps  in  two  different  pathways;  one 
amyloidogenic  and  one  non-amyloidogenic  (Zhang  et  al.,  2011).  The 
amyloidogenic pathway generates Aβ which mainly consists of 40-42 amino 
acid residues. The first cleavage of APP in the amyloidogenic pathway is 
performed  by  β-secretase  (Vassar  et  al.,  1999),  the  second  cleavage  is 
performed  by  γ-sectretase  and  this  generates  the  Aβ-peptide.  The  γ-
sectretase cleavage is heterogeneous and generates peptides ranging from 38 
to  43 r e s i d u e s ,  t h e  p r e d o m i n a n t  v a r i a n t s  a r e  t h e  A β1-40  and  the  more 
aggregation  prone  Aβ1-42  (Younkin,  1995).  In  the  non-amyloidogenic 
pathway the first step is performed by α-secretase (Sisodia, 1992) and the 
second step is performed by γ-sectretase (Haass et al., 1993). Mutations in 
APP (either outside or within the Aβ sequence) or in the presinilins (that 
are constituents of the γ-sectretase complex) alter the rate and/or the site of 
APP processing and thereby the generation and aggregation propensity of 
Aβ peptides and this will cause AD in younger persons as well. Patients with 
AD  first  lose  their  short-term  memory  followed  by  disorientation  and 
general recess in cognitive function as the disease progresses. The definitive 
AD diagnosis can only be made post mortem through a pathological exam of 
the brain where the neuropathological injuries can be established.  
 
The functions of APP and Aβ are still unknown and there is no cure or 
effective  therapy  for  AD.  The  therapies  available  today  are  only 
symptomatic, lot of work is being put into this challenging task of finding 
effective  therapies,  focusing  on  e.g. d e c r e a s i n g  t h e  p r o d u c t i o n  o f  t h e  
amyloidogenic  peptide  by inhibiting the β- o r  γ-secretases (Ghosh et al., 
2008, Fleisher et al., 2008), prevent aggregates from forming by inducing 
the production of chaperones (Ansar et al., 2007) or using small molecules 
or peptides as inhibitors of fibril formation (Nakagami et al., 2002). So far 
none of the strategies has proved to work.   25 
2  Present investigation 
2.1  Aims of this thesis 
The general aim of this thesis was to characterize and to find a function and 
binding partners to CTC and its BRICHOS domain.  
 
More specific aims were to: 
 
 
  Find a way to express and purify CTC from E.coli. 
 
  Characterize  the  binding  specificity  of  CTC  and  its  BRICHOS 
domain  towards  the  proSP-C  and  mature  SP-C  in  vitro a n d   in 
transfected cells. 
 
  Generate structural information about the BRICHOS domain. 
 
  Find out if the BRICHOS domains from proSP-C and Bri2 can act 
as chaperones against the Aβ-peptide. 
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2.2  Results  
2.2.1  Expression and purification of CTC and proSP-C BRICHOS (paper I 
and II) 
The C-terminal part of human proSP-C, residues 59-197, (CTC) (see 
figure 5 for sequence) was expressed as a fusion protein with thioredoxin- 
His6- and a S-tag in E.coli. Since CTC contains two disulfide bridges the 
Origami strain  with an  oxidizing environment  was  used. CTC is mainly 
found  as  an  insoluble  protein  even  though  it  is  expressed  with  tags 
commonly  used  to  increase  the  solubility.  It  is  probably  associated  with 
membranes, rather than present in inclusion bodies since it can be dissolved 
in 2M of urea, which is less than what is required for CTC denaturation 
(paper  III).  After  extensive  washing  on  Ni
2+-column,  removal  of  the 
thioredoxin- a n d  H i s -tag  and  further  purification  with  ionexchange 
chromatography, the purity was analysed by SDS-PAGE and nondenaturing 
PAGE. Also a mutant form of CTC, L188Q that is linked to ILD, was 
expressed  and  purified  in  the  same  way  as  the  wt  protein  (paper  I).  A 
construct that only contained the postulated BRICHOS domain (residues 
94-197) (Sanchez-Pulido et al., 2002) was also attempted to be produced. 
The  expression  of  proSP-C  (94-197)  however,  gave  a  low  amount  of 
protein  which  aggregated  easily  and  the  construct  was  therefore  later 
extended  to  residues  86-197  of  proSP-C  (Fitzen  et  al.,  2009),  and  this 
protein gave a higher yield and did not aggregate (paper II). 
 
Figure 5. The human proSP-C sequence. The first 23 amino acids represent the cytosolic 
N-terminal part. The amino acids with grey background correspond to the mature SP-C 
(residues  24-58).  Amino  acids  in  bold  represents  CTC  (residues  59-197)  and  bold  and 
underlined amino acids represent the BRICHOS domain (residues 90-197) as defined from 
the x-ray structure (paper IV). 
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2.2.2  Biochemical properties of CTC (paper III) 
 Recombinant CTC was analyzed for secondary and quaternary structure, 
domain  organization  and  stability  towards  denaturation  by  analytical 
ultracentrifugation (AUC), mass spectrometry (MS) and circular dichroism 
(CD) measurements. 
 
AUC showed that CTC is heterogeneous in size with the main species 
found being a trimer, but monomers, hexamers and nonamers could also be 
seen,  native  PAGE  also  verified  this.  The  quaternary  structure  was  also 
analyzed  with  electrospray  ionization  mass  spectrometry  (ESI  MS)  and 
trimers, hexamers, monomers and even dodecamers were seen.  
 
CTC contains four Cys residues and these have been proposed to form 
two  disulfide  bridges.  CTC  was  treated  with  trypsin  and  the  peptides 
derived  were  analyzed  with  matrix-assisted  laser  desorption/ionization 
(MALDI)  MS.  The fragments obtained showed that one of the two Cys 
residues at position 120 or 121 forms a disulfide with Cys148 and the other 
one with Cys189. Since Cys120 and Cys121 are right next to each other it 
is hard to assign the disulfide pairings any further. However, since Cys121 
and Cys189 are strictly conserved across all BRICHOS domains, it is likely 
that these two can form a disulfide bridge and that the other disulfide bridge 
is formed between Cys120 and Cys148 (paper III). This was later verified in 
the x-ray structure of the BRICHOS domain (paper IV). 
 
The stability of the protein was measured in several ways. Trypsin treated 
CTC  was  analyzed  by  MALDI  MS  and  the  sensitivity  towards  trypsin 
cleavage  differed  >1000  fold  in  different  parts  of  the  protein.  The 
BRICHOS  domain  is  much  more  resistant  to  cleavage  than  the  rest  of 
CTC. CD measurements of reduced and non-reduced CTC showed that 
the secondary structure is only affected significantly by urea or heat if the 
disulfides  are  reduced.    Differential  scanning  calorimetry  (DSC)  was  also 
used to determine the thermal stability of free and membrane bound CTC. 
These data indicated that membrane bound CTC is less stable than the free 
CTC (paper III).  
 
To  gain  further  insight  into  the  structural  properties  of  CTC  the 
interaction with the dye 1,1’-bis(4-anilino-5,5’-naphtahalenesulfonate) (bis-
ANS)  was  measured  by  fluorescence  spectroscopy.  The  fluorescence 
intensity  of  bis-ANS  depends  on  its  environment  and  the  intensity  was 
increased when CTC was added, proposing that CTC have hydrophobic   28 
surfaces that bis-ANS can bind to. Since CTC contains six Tyr residues and 
no  Trp,  fluorescence  resonance  energy  transfer  (FRET)  studies  were 
performed  to  see  if  these  Tyr  residues  are  located  close  to  the  bis-ANS 
binding site. The emission spectrum of CTC after excitation at 280 nm in 
the  presence  of  increasing  amounts  of  bis-ANS  was  recorded,  and  this 
showed a gradual decrease in Tyr fluorescence with a simultaneous increase 
in  the  bis-ANS  fluorescence.  Since  free  bis-ANS  does  not  emit  when 
excited at 280 nm this indicates an energy transfer from Tyr to bis-ANS. 
This  result  indicates  that  Tyr  residues  in  CTC  are  located  close  to  the 
binding site of bis-ANS (paper III). 
 
These data indicate that CTC is produced in E.coli as a folded and stable 
protein. CTC forms mainly trimers, contains two disulfide bridges and can 
only be denatured after reduction. CTC has a hydrophobic surface with 
tyrosine residues located close to a binding site for bis-ANS.   
2.2.3  Membrane association, substrate specificity and requirements for 
peptide binding (paper I, II, IV and V) 
Since, in proSP-C, CTC is located near the phospholipid membrane, the 
ability of CTC to associate with lipids was investigated. CTC can insert into 
phospholipid monolayers of palmitoyl-oleoyl-phosphatidylcholine (POPC) 
and  dipalmitoyl-phosphatidylcholine  (DPPC)/POPC  but  not  into 
monolayers of DPPC. The mutant L188Q could not insert into any of the 
monolayers tested. The POPC and DPPC/POPC monolayers are loosely 
packed,  similar  to  how  membranes  are  packed i n  t h e  e a r l y  s e c r e t o r y  
pathway. DPPC is tightly packed and this is similar to the more  ordered 
membranes  in  the  distal  secretory  pathway  and  in  particular  to  lung 
surfactant (paper IV). 
 
Both  CTC  and  CTC(L188Q)  was  incubated  with  lung  surfactant 
phospholipids with and without the SP-C peptide in an α-helical or non-
helical  conformation.  The  membrane  fraction  was  collected  by 
centrifugation,  and  the  pellets  and  supernatants  were  analyzed  by  SDS-
PAGE  and  western  blot.  In  the  presence  of  phospholipids  only,  or 
phospholipids  with  α-helical  SP-C  incorporated,  neither  wt  nor  mutant 
CTC bound to the membrane  but in the presence of phospholipids that 
contained non-helical SP-C, CTC  was found in the phospholipid  pellet. 
CTC(L188Q) was still only found in the supernatant, indicating that CTC 
but  not its mutant form  can interact  with  phospholipid membranes with 
non-helical SP-C incorporated (paper I).   29 
  
The  ability  of  CTC  to  change  non-helical  SP-C  into  an  α-helical 
conformation  was  measured  by  CD.  This  experiment  was  done  in  SDS 
micelles because of the hydrophobicity of the SP-C peptide. Far UV CD 
spectra of CTC in SDS micelles, or SDS micelles with α-helical or non-
helical  SP-C  with  and  without  CTC  present  were  recorded.  Calculated 
spectra of CTC plus α-helical or non-helical SP-C were compared to the 
corresponding spectra that were experimentally determined. The difference 
between the calculated and experimental spectra of CTC and non-helical 
SP-C showed a change in conformation that indicated an increase in helical 
content. The calculated and experimental spectra of CTC and α-helical SP-
C did not show any difference. CD measurements with SDS micelles with 
synthetic SP-C(1-21) (see fig. 5 for sequence) incorporated showed a typical 
β-strand structure. This peptide consists of the first 21 residues in the mature 
SP-C peptide. When CTC was added no change in secondary structure was 
seen (paper I and II).  
 
The substrate specificity of CTC was analyzed in several ways, among 
others a SPOT membrane was used. A SPOT membrane with overlapping 
peptide  decamers  corresponding  to  the  mature  SP-C sequence (proSP-C 
sequence 24-58, see fig. 5) and also some spots with the poly-Val sequence 
replaced with poly-Ala or poly-Leu was used. A SPOT membrane with the 
sequence LLIVVVVVVL truncated stepwise by one residue at the time was 
also analysed to see how many residues that are needed for CTC to bind. 
CTC binds to the hydrophobic stretches found in the SP-C poly-Val region 
and  it  can  also  bind  to  poly-Leu,  but  the  replacement  of  poly-Val  with 
poly-Ala abolishes the binding. CTC binds to peptides that are at least three 
residues long but the binding is much weaker than to peptides that are five 
or four residues long. Binding to the SPOT membrane with the proSP-C 
sequence was also investigated with CTC(L188Q) and with the proSP-C 
BRICHOS  domain, residues  86-197.  The BRICHOS  domain  bound  to 
the same  peptides as CTC while the mutant did not bind to any  of the 
peptides (paper II). CTC was also incubated with a SPOT membrane with 
homodecamers of different amino acids. CTC could bind to stretches of V, 
I, L, F, M and Y but not to A, W, G, P or T. CTC thus bind mainly to 
residues  that  promote  membrane  insertion  according  to  the  biological 
hydrophobicity  scale  (Hessa  et  al.,  2005) ( p a p e r  V ) .  A  peptide, 
KKVVVVVVVKK (K2V7K2) was also incubated with CTC and the mixture 
was analyzed  by  non-denaturing  PAGE  where  a  complex  between  CTC   30 
and K2V7K2 could be seen (paper I). Complexes between K2V7K2 and CTC 
were later confirmed by ESI-MS (Fitzen et al., 2009)(paper IV) 
 
The  peptide  SP-C33 ( S P -C  peptide  where  the  valines  have  been 
exchanged  for  leucines)  (Nilsson  et  al.,  1998),  including  the  sequence 
LLLLLLLLILLLILGALL  (target  peptide),  was  dissolved  in  either  aqueous 
formic  acid,  where  the  peptide  is  in  non-helical  conformation,  or  in 
ethanol,  where  it  is  α-helical.  The  peptide  was  then  blotted  onto  a 
membrane and incubated with CTC. A non-target peptide (IPCCPV) was 
used as a control. CTC binds to the target peptide if it is applied in non-
helical conformation but not if it is applied in an α-helical conformation 
(paper V).  
 
Taken  together,  these  experiments  show  that  recombinant  CTC  and 
proSP-C BRICHOS(86-197) but not CTC(L188Q) binds to stretches of 
hydrophobic amino acids that correspond to the TM part of mature SP-C 
but not to its polar cytosolic part. CTC can also bind to other stretches of 
residues that promote membrane insertion. The binding of CTC to a non-
helical  SP-C  peptide  in  micelles  results  in  increased  α-helical  structure. 
CTC  binds also to peptides in non-helical  conformation  outside  of lipid 
micelles. Finally, we have shown that CTC, but not a mutant associated 
with ILD, can associate with fluid phospholipid monolayers similar to those 
in the early secretory pathway. 
 
2.2.4  ILD is an amyloid disease and chaperone function of CTC and its 
BRICHOS domain (paper I, II and IV) 
The mature SP-C peptide has a discordant helix that has been proven to 
convert to β-sheet aggregates and amyloid like fibrils in vitro (Szyperski et 
al., 1998, Gustafsson et al., 1999). More than 50 mutations have been found 
in the proSP-C gene and most of them are located in the C-terminal part 
(paper IV).  
 
Lung samples from  ILD  patients  with mutant  proSP-C were analyzed 
with  congo  staining  and  tissue  with  the  I73T  or  the  Δ91-93  mutation 
showed green birefringence under polarized light. Immunolabeling of lung 
tissue sections with an antibody against mature SP-C, but not against N-
terminal  or  C-terminal  proparts,  stained  the  congophilic  depositions  and 
preabsorption with a synthetic peptide that corresponds to residues 24-41 in 
mature SP-C abolished the immunoreactivity (paper IV).   31 
 
CTC  can  bind  to  SP-C  in  non-helical  conformation  in  vitro and  th i s 
interaction  resulted  in  a  conformational  change  (papers  I,  II  and  V). 
Interactions between CTC and target proteins were also investigated in cell 
cultures. Stably transfected HEK293 cells expressing either wt proSP-C or 
the L188Q mutant, were transiently transfected with CTC carrying a signal 
peptide from proSP-B, directing it to the ER lumen. The mutant protein is 
apparently degraded rapidly and only a small fraction can be detected. When 
transfected with CTC a significant increase of proSP-C(L188Q) could be 
detected by western blot. The transfected cells expressing wt proSP-C did 
not  show  any  difference  in  the  amount  of  protein  detected.  This  result 
indicates  that  CTC  can  bind  to  mutant  proSP-C  in  trans a n d  t h e r e b y  
stabilize it and decrease the degradation (paper I). 
 
Further on, HEK293  cells, stably transfected  with  proSP-C(1-58) (see 
fig. 5 for sequence) and CTC with a signal peptide, or cells expressing only 
proSP-C(1-58) were analyzed. In cells that only express proSP-C(1-58), no 
protein could be detected in the cell lysate nor in the SDS insoluble/formic 
acid soluble fraction. Treating the cells with a proteasome inhibitor resulted 
in small amounts of detectable proSP-C(1-58) in the SDS-soluble fraction, 
indicating that the protein is synthesized but degraded rapidly. However in 
cells expressing both proSP-C(1-58) and CTC with signal peptide, proSP-C 
(1-58) is stabilized and rescued from degradation (paper II).  
 
In conclusion, we have shown that ILD due to mutations in proSP-C is 
a  new  amyloid  disease  and  this  is  likely  due  to  malfunction  of  the 
BRICHOS chaperone domain. Moreover, CTC can stabilize mature SP-C 
in HEK293 cells in trans and by doing so hinder it from degradation.    32 
2.2.5  Structure of proSP-C BRICHOS and model of Bri2 BRICHOS (paper 
IV and VI) 
 
Figure 6. The crystal structure of the proSP-C BRICHOS monomer. The structure 
shows a novel fold with a central five stranded β-sheet with one α-helix on each side. 
The structure of trypsin treated CTC was solved to 2.1 Å. There are no 
structural  homologues  in  the  protein  data  bank  and  the  fold  of  the 
BRICHOS  domain  from  proSP-C  has  not  been  observed  before.  The 
monomer structure shows a central β-sheet made up of five strands, β1-β4 
are antiparallel and β4 and β5 are parallel, with one α-helix on either side, 
one  on  face  A  and  the  other  on  face  B  (fig.  6).  The  two  helices  are 
amphiphilic, with the hydrophobic side packed against the β-sheet (α1) and 
the other side either exposed to the solvent or buried in the trimer interface 
(α2). The proSP-C residues 149-180 are situated in a presumably flexible 
loop that showed little electron density and were therefore not modeled in 
the structure. This loop region was also cleaved by trypsin present during 
crystallization. 
 
The residues conserved between proSP-C from different species coincide 
with many of the ILD mutations in CTC. The D105 is a strictly conserved 
residue  in  all  BRICHOS  domains,  and  mutation  of  it  is  associated  with 
ILD. This residue is located in a partially hydrophobic environment and is   33 
in  contact  with  the  N-terminal  of  helix  2.  Molecular  dynamics  (MD) 
simulations  were  carried  out  on  the  wt  monomer  and  trimer  and  on  a 
mutant monomer and trimer where the Asp had been replaced with an Asn. 
In the mutant monomer no major conformational changes occur, however 
in the wt monomer α2 unwinds and this eventually results in a movement 
of  α1  out  from  face  A,  leaving  the  hydrophobic  core  accessible  to  the 
solvent or possibly for substrate binding (fig. 7). The MD simulations of wt 
and mutant trimers did not show any unfolding, which indicates that the 
trimer state of the BRICHOS domain does not expose any hydrophobic 
surfaces and is unable to bind hydrophobic substrates.  
 
Figure 7. The structure of proSP-C BRICHOS after MD simulations.  Helix 2 has 
unfolded and this has lead to the movement of  α1 out from face A. 
The secondary structure predictions of all BRICHOS domains are very 
similar, and a homology model of the Bri2 BRICHOS domain could be 
built with the X-ray structure from the proSP-C BRICHOS as a template. 
In the central β-sheet there are some highly conserved residues located on 
face  A  but  there  are  also  some  interesting  differences  from  the  proSP-C 
BRICHOS domain. In particular some hydrophobic residues in proSP-C 
BRICHOS have been replaced with charged residue in Bri2.  
2.2.6  Chaperone function of BRICHOS domains against Aβ (paper V and VI) 
Molecular chaperones have been proven to have effects on, for example, the 
Aβ fibril formation and Nerelius et al. showed that CTC could bind to and   34 
stop the fibrillation of both Aβ and medin (Nerelius et al., 2009), and the 
interaction with Aβ was further characterized. 
 
Synthetic Aβ1-40 was incubated with or without CTC for seven days at 
37°C  with agitation.  Aliquots were taken  out at the beginning  and after 
seven days, centrifuged and the supernatants were analyzed by SDS PAGE 
and  with electron microscopy.  The gels show  both  Aβ and  CTC at the 
beginning,  but  after  seven  days  Aβ w i t h o u t  C T C  h a s  a g g r e g a t e d .  I f  
incubated  with  CTC,  the  supernatant  still  contains  Aβ  after  seven  days. 
Electron microscopy showed that Aβ alone has formed  fib rils after seven 
days but in the sample incubated with CTC no fibrils could be seen (paper 
V).  
 
For  further  experiments,  recombinant  peptides  that  starts  with  a 
methionine followed by human Aβ were used  (Walsh et al., 2009). The 
Bri2  BRICHOS  protein  used  corresponds  to  recombinant  human  Bri2, 
residues 90-236, expressed and purified from E.coli (Peng et al., 2010). The 
fibrillation  of  Aβ(M1-40)  and  Aβ(M1-42),  incubated  with  and  without 
CTC  or  Bri2  BRICHOS  at  different  concentrations  was  followed  by 
thioflavin T (ThT) fluorescence. The lag time for Aβ(M1-40) was highly 
affected  by  both  CTC  and  Bri2  BRICHOS  and the effects are seen far 
below equimolar concentrations for both CTC and Bri2 BRICHOS. The 
effect on Aβ(M1-42) is not as pronounced as for Aβ(M1-40) and higher 
amounts of both CTC and Bri2 BRICHOS are needed. These experiments 
show  that  both  proteins  are  potent  inhibitors  of  Aβ f i b r i l  f o r m a t i o n .  A  
stopping experiment was also performed where CTC or Bri2 BRICHOS 
was  added  at  different  time  points  to  the  fibrillating  Aβ p e p t i d e .  I f  t h e  
BRICHOS proteins were added during the lag time the aggregation was 
delayed. If the proteins were added during the early part of the elongation 
phase,  the  aggregation  halted,  but  if  BRICHOS  was  added  late  in  the 
elongation phase nothing happened.  
 
The  change  in  secondary  structure  during  Aβ f i b r i l  f o r m a t i o n ,  w a s  
followed by CD. CD spectra of Aβ(M1-40) alone show a gradual transition 
from random coil to β-sheet structure, but if any of the BRICHOS proteins 
were added, the transition is significantly delayed.  
 
 SEC was performed on Aβ(M1-40) alone or incubated with CTC or 
Bri2 BRICHOS at 37 °C for 20 hours. After 20 hour Aβ alone has formed 
fibrils but Aβ incubated with BRICHOS proteins still mainly migrates as a   35 
monomer with a small fraction eluting together with CTC or with Bri2 
BRICHOS (paper VI).  
2.2.7  A possible mechanism for the chaperone activity of proSP-C BRICHOS 
(paper VI) 
 
The  linker  region  in  proSP-C  is  highly  conserved  but  this  region  is 
missing  in  the  crystal  structure.  Hydrogen  deuterium  exchange  mass 
spectrometry ( H D X -MS)  was  performed  on  the  peptides:  K2V7K2, 
KKVVVVVKK (K2V5K2) and KKAAAAAAAKK (K2A7K2), incubated with 
CTC or proSP-C BRICHOS. K2V7K2 and K2V5K2 but not K2A7K2 became 
protected against HDX exchange in the presence of CTC. When the poly-
Val peptides bound to CTC the linker region also got protected from HDX 
(paper IV). These results indicate that the linker region is protected from 
HDX when the peptides are bound to CTC. A possible mechanism during 
proSP-C biosynthesis is that the linker region interacts with the TM region 
and  forms  a  strand-loop-strand  structure  (β-hairpin)  bound  to  the 
BRICHOS domain. Once the TM segment has folded into an α-helix the 
BRICHOS domain is released from the membranes and can be cleaved off 
by proteolysis (fig. 8). 
 
Figure 8. Postulated mechanism of proSP-C BRICHOS. The linker region and parts of 
the TM region form a β-hairpin structure that binds to face A in the BRICHOS domain (A). 
Once the TM region has formed an α-helix, the BRICHOS domain is released (B). The C-
terminal region of proSP-C gets proteolytically cleaved off and the BRICHOS domain can 
form a homotrimer (C).   36 
2.3  Discussion  
Hydrophobicity and low overall charge are two determinants for amyloid 
formation (Chiti et al., 2002) and are also hallmarks of TM regions (paper 
V). It has been suggested that VIFC biased segments (segments rich in Val, 
Ile, Phe and Cys) will promote the formation of inter- or intra-molecular β-
sheets  and  that  LAM  biased  segments  (rich  in  Leu,  Ala  and  Met)  will 
promote the formation of α-helices. Isolated VIFC regions were found in 
amyloid  cores  in  many  of  the  proteins  associated  with  diseases  in  man 
(Johansson et al., 2010). Leu and Ala are common in TM segments (Persson 
and Argos, 1994) and this is suggested to reduce the risk of forming β-sheets 
during biosynthesis (Johansson et al., 2010). The α-helix in mature SP-C is 
however essentially composed of a stretch of 13 Val or Ile (fig. 5)(Johansson 
et  al.,  1994).  Val  and  Ile  are  over-represented  in  β-sheet  and  under-
represented in α-helix structure, which may make α-helix formation in SP-
C less efficient (Mingarro et al., 2000). When folded and inserted into the 
membrane the α-helix is stable, but in solutions it is unstable and once it has 
unfolded it will spontaneously convert to β-sheet aggregates and amyloid-
like fibrils (Szyperski et al., 1998, Gustafsson et al., 1999), and we show in 
paper  IV  that  the  SP-C  peptide  can  form  amyloid  in  the  lung  of  ILD 
patients. Nature’s way of solving the problem of forming a discordant helix 
and  keeping  it  from  aggregation  seems  to  be  a  BRICHOS  chaperone 
domain in the C-terminal region of proSP-C, described in this thesis.  
 
CTC, CTC(L188Q), proSP-C BRICHOS(86-197) and Bri2 BRICHOS 
(90-236)  have  been  produced  in  E.coli.  Both  CTC  and  CTC(L188Q) 
needed to be dissolved in 2M of urea probably because of their association 
with membranes. Both CTC and CTC(L188Q) could thereafter be purified 
in a soluble state. ProSP-C BRICHOS(94-197) was purified to a low yield 
and this was probably because of the lack of the first four amino acids in the 
BICHOS  domain.  In  support  of  this,  when  extended  to  proSP-C 
BRICHOS (86-197) the protein yield increased. Bri2 BRICHOS (90-236) 
does not need to be purified with 2M of urea, probably because it is not 
associated with membranes.  
 
 Since mature SP-C is one of the most hydrophobic peptides known a 
lipid  environment  was  needed  for  its  analysis  and  surfactant  lipids,  SDS 
micelles and mixtures of DPPC and POPC have been used. The binding of 
CTC  to  non-helical  SP-C  in  a  lipid  environment  resulted  in  a 
conformational change. The binding of CTC to non-helical SP-C could be 
due  to  the  fact t h a t  n o n -helical  SP-C  does  not  insert  into  the  lipid   37 
environment and is therefore accessible for CTC to bind. However it was 
later shown that CTC binds to target peptides in non-helical conformation 
attached  to  membranes  but  not  to  the  same  peptide  if  it  is  in  α-helical 
conformation. The change in secondary structure seen with CTC and non-
helical  SP-C  could  occur  in  CTC  and  this  possibility  was  investigated 
further. A peptide (SP-C1-21) that lacks the second half of the SP-C poly-
Val stretch, does not give any change in secondary structure. This peptide 
contains a stretch of hydrophobic residues to which CTC can bind, but is 
not  long  enough  to  also  allow  a  stretch  of  nonbound  Val  in  which  a 
conformational change could take place. This indicates that the change in 
secondary structure seen occurs in the peptide and not in CTC. 
 
In the lung, the natural target substrate for CTC is likely the proSP-C 
TM region and we have shown that CTC can bind to SP-C and to poly-
Val sequences in lipids, in solution and bound to SPOT membranes. But 
the CTC substrate specificity stretches beyond a poly-Val sequence, and this 
broad substrate specificity could be explained by its function. CTC must be 
able to bind to any segment within the proSP-C TM region that is not in 
α-helical conformation to prevent β-sheet aggregation.  
 
The crystal structure of proSP-C was solved after years of attempts to 
obtain useful crystals. Residues 149-180 in proSP-C is probably in a flexible 
loop and not until this loop was cleaved off with trypsin did the BRICHOS 
domain form crystals. Trypsin treated CTC can associate with monlayers of 
POPC and POPC/DPPC as the wildtype, show the same CD spectrum as 
CTC and also binds to a triple Val peptide. These result show that treatment 
with trypsin has not affected the structure significantly and that the flexible 
loop  is  not  required  for  the  substrate  binding.  Many  of  the  conserved 
residues are located on face A and B and these could be of importance in the 
substrate binding. Interestingly many of the conserved residues in Bri2 are 
likewise located on face A and B, but on face A some of the hydrophobic 
residues  are  exchanged  for  residues  with  more  polar  side  chains.  These 
exchanges  correlate  well  with  the  target  substrates  of  proSP-C  and  Bri2 
BRICHOS,  proSP-C  BRICHOS  binds  to  highly  hydrophobic  peptides 
(papers I, II, IV and V) while Bri2 BRICHOS binds to more polar peptides 
(Peng et al., 2010).  
 
Asp 105 appears to be of importance by destabilizing α2 in the monomer 
and  this  leads  to  a  move  in  α1  away  from  face  A,  leaving  it  open  for 
substrates to bind (paper IV). FRET experiments showed that energy could   38 
be transformed from Tyr residues in CTC to bound bis-ANS (paper III) and 
there are four Tyr residues situated on face A. These data suggest that face A 
is the substrate binding site, but this needs to be verified by determination of 
a structure of a substrate-BRICHOS complex. 
  
In the asymmetric unit of the crystals, there are two trimers and a trimer 
state has been observed before with AUC and native PAGE. This seems to 
be a stable state and the MD simulations of the trimer showed that α-helix 2 
did not unfold and no move of α-helix 1 was observed. It is hard to imagine 
BRICHOS to act as a chaperone as a trimer, and a small monomer fraction 
has been seen with native PAGE, MS and AUC. It was also shown that 
oligo-Val peptides bind to monomeric proSP-C BRICHOS (Fitzen et al., 
2009). Using DSC, it was seen that the membrane bound CTC is less stable 
than CTC in solution and this could indicate that the membrane bound 
CTC is a monomer, but this needs to be experimentally verified. Others 
have shown by chemical cross linking of proSP-C in A549 cells that CTC 
does not oligomerize (Wang et al., 2002). We suggest that the BRICHOS 
domain  exerts  its  function  in  a  monomer  state  but  the  trimer  state  is 
important as a “capped” state. The proSP-C BRICHOS domain can bind 
to hydrophobic stretches and in the crowded interior of the cell capping is 
needed to avoid inadvertent binding to any hydrophobic regions. A capping 
mechanism is utilized by many chaperones, like the sHSPs (Haslbeck et al., 
2005).  
 
The proSP-C TM region has a high barrier for α-helix formation since it 
mainly consists of Val residues (Hosia et al., 2002, Szyperski et al., 1998). 
When BRICHOS binds to the TM region the energy barrier is suggested to 
get reduced, making formation of an α-helix energetically favorable (paper 
II).  BRICHOS  thus  both  assists  the  TM  region  to  fold  correctly  and 
prevents  it  from  forming  aggregates.  This  is  compatible  with  BRICHOS 
being an intramolecular, steric chaperone. Membrane-integrated chaperones 
that bind to TM regions have been described. These chaperones bind to 
TM helices and prevent them from aggregating by holding them until the 
TM helices find their right binding  partner (Kota  and  Ljungdahl, 2005). 
ProSP-C BRICHOS differs from these chaperones by not being an integral 
membrane protein and by binding to nonhelical conformations.  
 
It has been shown (Peng et al., 2010, Nerelius et al., 2009) that both 
recombinant CTC and Bri2 BRICHOS bind to Aβ. We have confirmed 
that  BRICHOS  domains  of  proSP-C  and  Bri2  bind  to  Aβ,  which  then   39 
aggregates significantly slower than it does on its own. The main effect is 
seen on the lag phase and we suggest that BRICHOS binds to dimeric and 
oligomeric  Aβ s p e c i e s  o n  p a t h w a y  t o  f i b r i l  f o r m a t i o n .  T h e  i n t e r a c t i o n  
between BRICHOS and Aβ increases the rate of oligomer dissociation and 
this  result  in  a  sustained  pool  of  monomeric  Aβ.  Others  have  described 
similar mechanisms for HSP 70 that is active in sub stoichiometric amounts 
and interact with intermediates formed in the fibril formation process (Evans 
et al., 2006).  Keeping  Aβ in a monomeric form seems attractive from a 
therapeutic point-of-view, independently of whether fibrils or oligomers are 
considered to be the toxic species (Hardy, 2002, Hardy and Higgins, 1992).  
 
We  have  shown  that  the  BRICHOS  domain  from  Bri2  seems  to  be 
more  effective  towards  Aβ th an th e  B RI C HO S d om a i n f rom  p roS P-C. 
This  is  probably  due  to  the  difference  in  sequence  specificity  between 
proSP-C  BRICHOS  and  Bri2  BRICHOS.  Bri2  BRICHOS  has  more 
charged residues than proSP-C BRICHOS in the postulated binding site 
and binds better to charged peptides. Peng et al. showed that recombinant 
Bri2  BRICHOS  binds  to  the  ABri23  peptide  (Peng  et  al.,  2010).  This 
peptide  shows  a  strand-loop-strand  conformation  in  secondary  structure 
predictions and a strand-loop-strand conformation is needed in Aβ for the 
formation of cytotoxic oligomers and fibrils (Sandberg et al., 2010). Thus, 
this seems to be a common binding motif for the proteins in the BRICHOS 
family since all proteins (except group A and proSP-C) in this family has a 
C-terminal  region  with  a  suggested  strand-loop-strand  conformation 
(Hedlund  et  al.,  2009).  The  TFF1  contains  a  strand-loop-strand  motif 
(Polshakov et al., 1997) and this motif may be recognized by GKN2, which 
has been shown to bind to TFFI (Westley et al., 2005). 
 
 
 There are over 50 known mutations in the proSP-C gene, most of them 
are located in the BRICHOS domain and many of them co-localize with 
conserved residues. Amyloid fibrils have been seen in the lung samples from 
patients  suffering  from  ILD.  In  these  cases  the  proSP-C  gene  (SFTPC) 
carried  a  mutation,  either  the  I73T  mutation  or  the  Δ91-93  deletion 
mutation.  The  I73T  mutation  is  located  in  the  linker  region  and  this 
mutation could maybe abolish the binding of the postulated β-hairpin motif 
to  the  BRICHOS  domain,  or  prevent  it  from  forming.  The    Δ91-93 
deletion  mutation  is  located  in  the  BRICHOS  domain  in  the  trimer 
interface.  This  could  hinder  the  trimer  from  capping  the  hydrophobic 
monomer  surface,  which  then  binds  inappropriately  to  hydrophobic   40 
constituents.  The  capping  mechanism  proposed  for  proSP-C  BRICHOS 
resembles  that  of  the  sHSPs, w h i c h  e x i s t  i n  a n  e q u i l i b r i u m  b e t w e e n  
oligomeric and dimeric states. The packaging of sHSPs into dimeric units 
has been suggested as a control mechanism and the exposure of hydrophobic 
surfaces in the monomeric state may be responsible for chaperone activity 
(Benesch et al., 2008). Mutations in the sHSPs has been shown to increase 
the chaperone activity and enhanced binding to substrate proteins, and these 
mutations also resulted in an increase of the monomer state which might 
result  in  unwanted  formation  of  sHSP-substrate  complexes,  possibly 
interfering with their normal function (Almeida-Souza et al., 2010). 
 
   41 
3  Conclusions and future perspectives 
3.1  Conclusions 
  CTC can be produced in E.coli and purified into a folded protein. 
CTC forms mainly trimers, contains two disulfide bridges and can 
only be denatured after reduction. 
 
  CTC and its BRICHOS domain bind to stretches of hydrophobic 
amino acids that correspond to the TM part of mature SP-C. CTC 
can also bind to other stretches of residues that promote membrane 
insertion and CTC can stabilize mature SP-C in HEK293 cells in 
trans and by doing so hinder it from degradation. 
 
  ILD caused by mutations in the proSP-C gene is a novel amyloid 
disease. 
 
  The proSP-C BRICHOS structure shows a central β-sheet made 
up of five strands with one α-helix on either side. The two helices 
are amphiphilic, with the hydrophobic side packed against the β-
sheet and the other side either exposed to the solvent or buried in 
the trimer interface. 
 
  The BRICHOS domains from proSP-C and Bri2 can bind to Aβ 
and keep it from forming fibrils for a long period of time. 
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3.2  Future perspectives 
Aggregation  and  misfolding  of  proteins  is  linked  to  a  large  number  of 
diseases either by a loss of function or gain of toxic function. Nature has 
tried to solve the problem with disease causing aggregating proteins by a 
number of strategies,  one  of them being the molecular chaperones.  This 
thesis  has  described  a  novel  anti-amyloid  chaperone,  the  BRICHOS 
domain. Since this BRICHOS domain has been shown to inhibit the Aβ 
peptide  from  forming  fibrils  and  to  inhibit  medin  from  forming  fibrils 
(Nerelius et al., 2009), this domain might be interesting from a therapeutic 
point-of-view, a possibility that deserves further studies.  
 
It is suggested that the BRICHOS monomer state is the active state and 
finding proof of this possibility, e.g. b y mutating the D105 or chemically 
cross-linking the monomers into trimers and investigate activativity would 
be interesting. Proximity ligation assay (PLA) in cell lines to investigate if 
the trimer or monomer exists in vivo likewise seems warranted. 
 
Most of the analysis so far performed, have been in vitro experiments.  To 
test  the  BRICHOS  domain  in  animal  models  is  required  for  further 
understanding of its function. The effect of the BRICHOS domain in a 
Drosophila model that express Aβ has been initiated and treating transgenic 
Aβ-expressing mice with BRICHOS domain is tempting. 
 
The substrate binding surface of the proSP-C BRICHOS  domain  has 
only been deduced from structure-function analyses, and its exact nature 
need to be verified, e.g. by solving a structure with bound substrate with X-
ray diffraction or NMR methods. There are lot of mutations in the proSP-
C gene and how these affect the structure is still to a large extent unknown.  
 
The structural data of Bri2 BRICHOS are based on the model from the 
proSP-C  BRICHOS  structure,  and  the  structure  of  Bri2  BRICHOS 
domain,  like  those  of  all  other  BRICHOS  domains,  remain  to  be 
experimentally studied.    43 
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